Bobbi Drais Promoted to Vice President, Regulatory Affairs for HEALTHPOINT, Ltd.

FORT WORTH, Texas, May 7 /PRNewswire/ – HEALTHPOINT, Ltd., a DFB Pharmaceuticals, Inc. company, has announced the promotion of Bobbi Drais to Vice President of Regulatory Affairs. Ms. Drais, with 15 years of regulatory experience, was most recently Senior Director of Regulatory Affairs for the company.

Since joining Healthpoint in 2003, Ms. Drais has achieved landmark regulatory success for DFB and Healthpoint. Ms. Drais initially established the regulatory department for Healthpoint. She and her team secured new drug approval (NDA) and marketing authorization approval (MAA) for ATRALIN(TM) (tretinoin) Gel in the US and Europe, respectively, the first Healthpoint proprietary product to achieve such approval. Ms. Drais was also instrumental in gaining regulatory approval of Collagenase SANTYL(R) Ointment in Canada.

“With Bobbi at the helm of all regulatory functions, I have great confidence that Healthpoint can seamlessly continue along its trajectory of success,” said Travis E. Baugh, President of Healthpoint. “We’re fortunate to have such a seasoned professional in this role as we navigate the regulatory waters. We count on her tremendously.”

Prior to joining the DFB family of companies, Ms. Drais was Regulatory Affairs Manager for Galderma Laboratories, LP, Carrington Laboratories, Inc. and Smith & Nephew, Inc.

Ms. Drais graduated from Messiah College in Grantham, Pa., with a Bachelor of Science degree in biology. She also earned a Master of Science degree in microbiology from the University of South Florida in Tampa, Fla. Ms. Drais maintains memberships in the Regulatory Affairs Professional Society and the Drug Information Association, and she holds a Regulatory Affairs Certification (RAC).

Since 1992, HEALTHPOINT has been dedicated to innovative technologies for the prevention and treatment of acute, chronic and burn-related wounds. The company is presently focused on the research and development of novel biologics and pharmaceuticals intended to improve clinical and quality of life outcomes. Currently marketed products include: Collagenase SANTYL(R) Ointment, OASIS(R) Wound Matrix, HYDROFERA BLUE(R) Bacteriostatic Wound Dressings, and SURGICEPT(R) Waterless Surgical Hand Antiseptic. HEALTHPOINT is also committed to advancing the care and treatment of wounds through support of industry leading continuing education from THE WOUND INSTITUTE(R). To learn more about this comprehensive and award winning educational resource, please visit TheWoundInstitute.com(R). HEALTHPOINT is a DFB Pharmaceuticals, Inc. affiliate company, and is based in Fort Worth, Texas. For more information, visit the HEALTHPOINT website at www.healthpoint.com.

SOURCE HEALTHPOINT, Ltd.